Skip to main content

Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma

Buy Article:

$51.00 plus tax (Refund Policy)



Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumours (NETs), and patients usually present with symptoms secondary to hypoglycaemia. Octreotide has been widely used in the symptomatic treatment of patients with pancreatic NETs, including insulinomas. We describe a case of a patient with a metastatic NET, subsequently identified as a malignant insulinoma, who developed severe hypoglycaemia after treatment with long-acting octreotide.

Keywords: hypoglycaemia; insulinoma; octreotide

Document Type: Research Article


Affiliations: Division of Haematology and Medical Oncology, Peter MacCallum Cancer Centre

Publication date: June 1, 2007

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more